BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis’s achondroplasia drug Yuviwel. The settlement resolves litigation currently pending in numerous jurisdictions, including a Section 337 investigation by the US International […]Read More
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
